Log inTry free

Editas Medicine (EDIT) stock

Market cap $387M

$2.73
-2.15%

Market closed. Prices as of today's close.

Quality Score
-2
Poor
In its industry
#164of 300
Biotech

EDIT's Quality Score fell 3 points on Tue, Oct 6, to -2. Closed below its falling 200-day average. 1 more reason, for Pro members.

Next2027“…1, the dose-finding portion of the Phase 1/2 trial of EDIT-401, with topline data results available in 2027…”Trial data · 8-K, Aug 5
Cash$212M, about 7 quarters at the last year's spendingOn Jun 30 · the company says “into the second half of 2028”

Follow EDIT's trial news. Pro members can get an alert when Editas Medicine files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when EDIT files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Since its Nov 2021 high

Down 93%, while sales grew 59%.

4 more reasons behind EDIT's -2, for Pro members

Cash$212M, about 7 quarters at the last year's spendingOn Jun 30 · the company says “into the second half of 2028”

What's next for EDIT, and how long its cash lasts

From Editas Medicine’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2027“Editas plans to complete enrollment in Part 1, the dose-finding portion of the Phase 1/2 trial of EDIT-401, with topline data results available in 2027.”Trial data · 8-K, Aug 5

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
EDIT-401

2 more trials, 39 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 7 quarters

$212M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “into the second half of 2028” (8-K, Aug 5).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Aug 31, 2026)
  • At-the-market share sales program (S-3, filed Aug 31, 2026)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CFO Amy Parison sold 453 shares on Sep 3, under a planned sale. 10 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Gilmore O'Neill buys or sells

For Pro members: every trade, and Gilmore O'Neill’s 10 filings and quotes.

Get an optional alert when EDIT files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 113 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why EDIT scores -2

PoorTransition, 3 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • +3Chart checks 3 of 14 firing right now, one point each
  • −3Long-term trend below a falling 200-⁠day average, down over one year, down over two years
  • Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Profit, Persistence, and News.

What every line is worth, and the reason behind it, on EDIT and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:05 PM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Mon Nov 9, after the close

After its last 4 reports it closed +6.2% on average, higher 4 of 4 times.

What would turn EDIT's score around: 9 things, for Pro members

Alert me when EDIT's Quality Score turns up

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on EDIT and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

EDIT has 3 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on EDIT, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1449.0

    Above 30, below 50.

  • MACD (12, 26, 9)Above signal

    Crossed above its signal line 1 session ago.

  • 50-day average$2.84

    The price is 3.9% below it.

  • 200-day average$2.64

    The price is 3.4% above it. The 50-day is above the 200-day, since May 5.

  • ADX 1420.9

    Under 25, with +DI above -DI.

  • Support$2.71

    Swing low from Aug 14, 0.5% below the price.

  • Resistance$2.77

    Swing high from Mar 10, 1.3% above the price.

  • Bollinger Bands (20, 2)Inside

    The bands run from $2.48 to $2.89.

  • Volume0.9x

    Against its 20-day average, for the time of day.

How EDIT ranks in Biotech

EDIT is #164 of 300 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does EDIT report earnings, and what happens after?

Expected to report Mon Nov 9, after the close (in 34 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 5, 2026After close+2.5%+5.5%+3.3%
May 5, 2026Before open+0.7%+1.3%+2.0%
Mar 9, 2026Before open-1.0%+16.0%+22.0%
Nov 10, 2025Before open+9.5%+2.0%+5.3%

The gap is the next open against the close before the report; the reaction is where that session closed. EDIT closed higher after 4 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

EDIT's officers and directors

Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.

See insider trades by person

About Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

87 employeesCambridge, MAeditasmedicine.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of EDIT's score, with the points and the reason
  • All 14 checks on EDIT and on all 3,244 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on EDIT
See all 14 checks on EDITSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.